Periprocedural management of oral anticoagulation in patients with atrial fibrillation: Approach in the era of new oral anticoagulants

Canadian Journal of Cardiology

Volumn 29, Issue 7 SUPPL, 2013, Pages

  Healey, Jeff S ^a   Brambatti, Michela ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 7A; DABIGATRAN; FEIBA NF; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NOVOSEVEN RT; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; ERYTHROCYTE TRANSFUSION; HEART ATRIUM FIBRILLATION; HUMAN; PREVALENCE; REVIEW; THROMBOEMBOLISM;

EID: 84879522289     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.02.021     Document Type: Review

References (39)

1. Wolf P.A., Dawber T.R., Thomas H.E., et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978, 28:973-977.
2. Krahn A.D. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-Up Study. Am J Med 1995, 98:476-484.
3. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., Hart R.G. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995, 155:469-473.
4. Furberg C.D., Psaty B.M., Manolio T.A. The prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994, 74:236-241.
5. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in the incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
6. Nieuwlaat R., Capucci A., Lip G.Y., et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006, 27:3018-3026. Euro Heart Survey Investigators.
7. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillaiton Guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
8. Coppens M., Eikelboom J.W., Hart R.G., et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are likely to benefit from oral anticoagulant therapy. Eur Heart J 2013, 34:170-176.
9. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation: developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
10. Keogh C., Wallace E., Dillon C., Dimitrov B.D., Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischemic stroke: a systematic review and meta-analysis. Thrombo Haemost 2013, 106:528-538.
11. Olesen J.B., Lip G.Y., Lindhardsen J., et al. Risk of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a "real world" national cohort study. Thrombo Haemost 2011, 106:739-749.
12. Wyse D.G. It's health care delivery, stupid: implementing the new Canadian Cardiovascular Society Atrial Fibrillation Treatment Guidelines. Can J Cardiol 2011, 27:14-18.
13. Chugh S.S., Blackshear J.L., Shen W.K., Hammill S.C., Gersh B.J. Epidemiology and natural history of atrial fibrillation: clinical implications. JAm Coll Cardiol 2001, 37:371-378.
14. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151. the RE-LY Steering Committee and Investigators.
15. Healey J.S., Eikelboom J., Douketis J.D., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012, 126:343-348.
16. Siegal D., Yudin J., Kaatz S., Douketis J.D., Lim W., Spyropoulos A.C. Perioprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromoboembolic rates. Circulation 2012, 126:1630-1639.
17. Robinson M., Healey J.S., Eikelboom J., et al. Post-operative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol 2009, 32:378-382.
18. Devereaux P.J., Chan M.T., Alonso-Coello P., et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012, 307:2295-2304.
19. Birnie D., Healey J.S., Krahn A., et al. Bridge or continue coumadin for device surgery: a randomized controlled trial rationale and design. Curr Opin Cardiol 2009, 24:82-87.
20. Healey J.S., Hart R.G., Pogue J., et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008, 39:1482-1486.
21. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:326S-350S. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel.
22. Omran H., Bauersachs R.M., Rubenacker S., Goss F., Hammerstingl C. The HAS-BLED score predicts bleeding during bridging of chronic oral anticoagulation: results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thrombo Haemost 2012, 108:65-73.
23. Batra R., Maino A., Ch'ng S.W., Marsh I.B. Perioperative management of anticoagulated patients having cataract surgery: national audit of current practice of members of the Royal College of Ophthalmologists. JCataract Refract Surg 2009, 35:1815-1820.
24. Dewan K., Bishop K., Muthukrishnan A. Management of patients on warfarin by general dental practitioners in South West Wales: continuing the audit cycle. Br Dent J 2009, 206:214-215.
25. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombo Haemost 2010, 103:1116-1127.
26. Connolly S.J., Eieklboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364:806-817.
27. Patel M.R., Mahaffey W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
28. Stangier J., Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012, 23:138-143.
29. Siegal D.M., Crowther M.A. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2012, 34:489-498.
30. Granger C.B., Alexander J.H., McMurrary J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992. ARISTOTLE Committees and Investigators.
31. Pfizer Canada Inc and Bristol-Meyers Squibb Canada. Product monograph: Eliquis (apixaban tablets). Available at: Accessed February 1, 2013. http://www.pfizer.ca/en/our_products/products/monograph/313.
32. Bayer Inc. Product monograph: Xarelto (rivaroxaban tablet). Available at: Accessed February 1, 2013. http://www.bayer.ca/files/Xarelto%20English%2012APR2013.pdf?#.
33. Pengo V., Crippa L., Falanga A., et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: a consensus document of the Italian Federation of Thrombosis Centres (FCSA). Thrombo Haemost 2011, 106:868-876. Italian Federation of Thrombosis Centres.
34. Turpie A.G., Kreutz R., Llau J., Norrving B., Haas S. Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thrombo Haemost 2012, 108:876-886.
35. Connolly S.J., Gillis A.M. Therapies for the prevention of stroke and other vascular events in atrial fibrillation and atrial flutter. Can J Cardiol 2005, 21:71B-73B.
36. Warkentin T.E., Margetts P., Connolly S.J., Lamy A., Ricci C., Eikelboom J.W. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012, 119:2172-2174.
37. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
38. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42:3594-3599.
39. Marlu R., Hodaj E., Paris A., Albaladejo P., Cracowski J.L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover exvivo study in health volunteers. Thrombo Haemost 2012, 108:217-224.